ArticleJugan geon-gang gwa jilbyeong2024
[Genetic Diversity and Drug Resistance of Human Immunodeficiency Virus from Newly Diagnosed Human Immunodeficiency Virus-positive in Korean, 2022-2023].
Article in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Human Immunodeficiency Virus-1 Subtype Distribution and Antiretroviral Drug Resistance among Treatment-naive Individuals in the Republic of Korea (2024-2025).Public health weekly report · 2026Article
- HIV Treatment Paradigm Shifts over the Past 40 Years.Jugan geon-gang gwa jilbyeong · 2025Review
- HIV-1 Genetic Diversity and Transmitted Drug Resistance Mutations in ART-Naïve Individuals in South Korea from 2021 to 2024.Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus (HIV) infection can cause acquired immunodeficiency syndrome (AIDS). The high HIV mutation rate is a major hurdle in vaccine and drug development. In this study, we analyzed the distribution of HIV genotypes and drug resistance mutations in a Korean patient newly infected with HIV between 2022 and 2023. The Korean clade HIV genotype B type (KR-B) was the most predominant HIV genotype, accounting for 70.7% in 2018-2019. However, recent analysis results have confirmed that the distribution of genotypes other than KR-B will increase to 39.2% and 40.5% from 2022 and 2023, respectively. In particular the diversity of genotypes is expected to gradually increase as many recombinants which were not detected in 2018-2019 such as CRF_01B, CRF_0263, and CRF_01BC. In addition, the drug resistance rate in treatment-naive infected individuals is predicted to be 5.2% in 2022 and 6.7% in 2023. HIV drug resistance among the different classes of antiretroviral drugs was not significantly different. Therefore, the proportion of resistance mutations in the main drug classes will remain largely unchanged from 2022 to 2023. In conclusion, it is crucial to periodically analyze the current status of domestic and epidemiological correlations. Also we have to continuously improve process because of the increasing genetic diversity. A surveillance system must be established through periodic monitoring to analyze drug resistance rates that reflect the latest trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.